Actively Recruiting
Nicotine Patch Plus Nicotine Mouth Spray Versus Nicotine Reduction for Vaping Cessation
Led by University of Auckland, New Zealand · Updated on 2025-04-03
774
Participants Needed
1
Research Sites
109 weeks
Total Duration
On this page
Sponsors
U
University of Auckland, New Zealand
Lead Sponsor
U
University College, London
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research focuses on maximizing the chances of successfully quitting vaping. A large, pragmatic community-based clinical trial is planned in New Zealand to build on existing evidence from previous vaping and smoking cessation research undertaken by the study team. The effectiveness of combination nicotine replacement therapy (NRT) compared to nicotine tapering on vaping abstinence has not yet been investigated, but both provide an opportunity to increase success with vaping cessation, especially when combined with written behavioural support to further boost quit rates. The planned trial will test whether using combination NRT will help more New Zealanders to quit vaping long-term, compared with a vape nicotine tapering plan. Participants in both groups will also receive written vaping cessation behavioural support.
CONDITIONS
Official Title
Nicotine Patch Plus Nicotine Mouth Spray Versus Nicotine Reduction for Vaping Cessation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Live in New Zealand.
- Vape nicotine at least weekly (one or more days out of the past seven days).
- Used to smoke (i.e. they have smoked tobacco regularly but not at all in the past six months) or have never smoked (i.e., they have never been a regular user of smoked tobacco, defined as less than 100 cigarettes in their lifetime).
- Are aged ≥16 years.
- Are motivated to quit vaping in the next eight weeks.
- Are able to provide consent.
- Have access to the internet via a computer or smart phone.
- Are a registered patient at a New Zealand medical facility.
You will not qualify if you...
- They have another person in their household currently enrolled in the study.
- They smoke tobacco currently or were a recent regular user of tobacco.
- They are enrolled in another vaping cessation programme/trial.
- They self-report having had a serious cardiovascular event, or hospitalisation for a cardiovascular complaint, in the previous four weeks (e.g. stroke, myocardial infarction, unstable angina, cardiac arrhythmia, coronary artery bypass graft and angioplasty).
- They self-report uncontrolled hypertension.
- They have a strong preference to use/not use NRT or nicotine tapering.
- They are current users of smoking cessation pharmacotherapy (e.g. NRT, varenicline, cytisine, nortriptyline [including if it is used for a different indication], and amitriptyline [as it converts to nortriptyline].
- They are currently enrolled in another vaping cessation programme/trial.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
School of Population Health, Faculty of Medical and Health Sciences, University of Auckland
Auckland, New Zealand, 1142
Actively Recruiting
Research Team
A
Amanda Calder, PhD
CONTACT
C
Chris Bullen, PhD, MBChB
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here